Literature DB >> 12126015

Otologic facial palsy: etiology, onset, and symptom duration.

Ellen Kvestad1, Karl J Kvaerner, Iain W S Mair.   

Abstract

To estimate the occurrence of otogenic facial palsy, we performed a retrospective case record study of all patients hospitalized for otogenic facial palsy in the period 1989 to 1999 at Ullevål University Hospital, which is the only referral hospital for patients with otologic sequelae in Oslo. The facial palsy was a complication of acute otitis media in 10 patients (56%), of acute mastoiditis in 3 patients (17%), of secretory otitis media in 3 patients (17%), and of chronic otitis media in 2 patients (11%). In half of the patients, complete facial palsy was found at the time of diagnosis. Sixteen patients (89%) reported a gradual onset of the facial palsy. The mean duration of otologic symptoms before the onset of facial palsy was 3 days (range, 1 to 9 days), and the median time to remission was 9 weeks (range, 2 to 96 weeks). Total remission was achieved in all patients who received follow-up. Although most patients recover within a few weeks, some patients have long-lasting facial palsy. Multicenter studies are needed to increase the sample size and to identify predictors of facial palsy duration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126015     DOI: 10.1177/000348940211100706

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  3 in total

Review 1.  Adenoidectomy and tympanostomy tubes in the management of otitis media.

Authors:  Petri S Mattila
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

2.  Facial Nerve Paralysis in Acute Suppurative Otitis Media-Management.

Authors:  Sriranga Prasad; K V Vishwas; Swetha Pedaprolu; R Kavyashree
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-01-06

Review 3.  Complications of acute otitis media in children.

Authors:  Kimmo Leskinen
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.